 Kansas City Star | Novartis earnings fall 47% but pleased with pipeline Pharma Times Better news came from sales of Lucentis (ranibizumab) for the treatment of age-related macular degeneration, which shot up 40% to $550 million, while kidney cancer drug Afinitor (everolimus) brought in $133 million, up 66%. Novartis delivers strong underlying financial performance in 2011, expects ... |
